AUS
NZ
UK
CA
USA
IND
Healt
ASX All Ordinaries Updates: Racura Study Focus
March 27, 2026 03:02 PM AEDT| By SamRacura advances cancer research through MYC-focused studies and academic collaboration, highlighting biotechnology innovation within the ASX All Ordinaries healthcare sector.
Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil® Gains Commercial Traction
March 27, 2026 02:30 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast has scheduled its inaugural R&D Day on 8 April 2026 in New York City.,The company reported H1 FY2026 revenue of US$51.3 million, driven by Ryoncil® launch.,Ryoncil® achieved gross sales of US$57.0 million following U.S. commercia...
ASX All Ords Healthcare Update: Lumos Diagnostics FDA Clearance
March 27, 2026 12:11 PM AEDT| By SamtaLumos Diagnostics expands healthcare diagnostics footprint through FDA CLIA waiver for FebriDx, enabling broader access to rapid infection testing across diverse clinical environments.
Radiopharm All Ordinaries Clinical Trial Milestone Update
March 27, 2026 11:29 AM AEDT| By SamRadiopharm advances clinical development with first patient dosing of its RAD compound, reflecting ongoing healthcare sector activity within the All Ordinaries framework.
Lumos Capital Move Sparks Market Attention
March 27, 2026 11:23 AM AEDT| By SamLumos Diagnostics’ capital expansion highlights evolving market dynamics, improved liquidity potential, and strategic positioning within Australia’s healthcare diagnostics sector.
CSL & Pro Medicus: Healthcare Stocks in Focus Now
March 26, 2026 06:29 PM AEDT| By SamAn in-depth look at CSL and Pro Medicus, highlighting business models, valuation insights, and their growing importance in Australia’s healthcare-driven market landscape.
Micro-X Cash Strategy in Focus Amid Growth Push
March 26, 2026 05:34 PM AEDT| By SamAn in-depth look at Micro-X’s cash flow trends, growth trajectory, and funding outlook, exploring how financial strategy aligns with broader movements across the Australian equities landscape.
Pro Medicus Journey Gains Focus Within ASX 200 Healthcare Space
March 26, 2026 04:31 PM AEDT| By SamA healthcare technology firm within the Australian market has drawn attention due to notable valuation movement, driven by imaging software adoption, global contracts, and its presence in major ASX indices.
BCAL Diagnostics Expands Avantect Testing Across National Pathology Networks
March 26, 2026 03:51 PM AEDT| By SamBCAL Diagnostics (ASX:BDX) expands Avantect testing across Sonic and Healius networks, enhancing early cancer detection with advanced genomic and AI-driven diagnostics.
Is Actinogen Medical (ASX:ACW) active in All Ordinaries?
March 26, 2026 02:33 PM AEDT| By SamActinogen Medical advances share quotation activity, reflecting capital management and healthcare sector engagement within the All Ordinaries framework.
ASX 300 Spotlight: Mesoblast (ASX:MSB) Sector Focus
March 26, 2026 02:11 PM AEDT| By SamMesoblast and emerging companies reflect healthcare sector activity, highlighting clinical development and market participation within ASX 200 and ASX 300.
ResMed Share Price Insights: Is RMD Worth Watching in 2026?
March 25, 2026 05:15 PM AEDT| By SamA detailed analysis of ResMed CDI (ASX:RMD) share price, covering financial performance, valuation metrics, and business outlook to understand its position in the evolving healthcare technology sector.
Mayo Momentum Lifts 4DMedical’s US Expansion Story
March 25, 2026 04:55 PM AEDT| By Sam4DMedical advances US growth with a major hospital deployment, boosting visibility, adoption momentum, and confidence in its lung imaging technology across clinical settings.
Pacific Edge Expands Share Base Amid ASX 200 Market Activity
March 25, 2026 04:45 PM AEDT| By Team Kalkine MediaPacific Edge progresses with additional ordinary share quotation, highlighting developments in the healthcare segment within the Australian equity ecosystem and broader market participation.
Algorae Pharmaceuticals (ASX:1AI) Rises as Cash Burn Eases
March 25, 2026 04:41 PM AEDT| By SamAlgorae Pharmaceuticals trends within all ordinaries show controlled cash usage, funding considerations, and biotechnology sector movement as development progresses without established revenue streams.
4DMedical Gains Momentum with Landmark US Healthcare Expansion
March 25, 2026 04:24 PM AEDT| By Sam4DMedical advances its US expansion through a key hospital collaboration, strengthening clinical validation and accelerating adoption of its lung imaging technology across prominent healthcare institutions.
Algorae Pharmaceuticals (ASX:1AI) Trends in the All Ordinaries
March 25, 2026 03:54 PM AEDT| By SamAlgorae Pharmaceuticals (ASX:1AI) emphasizes research, cash oversight, and sector positioning, contextualized by movements in the all ordinaries chart and broader ASX developments.
4DMedical (ASX:4DX) Advances Healthcare Imaging
March 25, 2026 02:57 PM AEDT| By Sam4DMedical’s engagement with Mayo Clinic highlights advancements in respiratory imaging and reflects healthcare innovation within the All Ordinaries market framework.
Is Algorae Pharma (ASX:1AI) shaping All Ords biotech focus?
March 25, 2026 01:00 PM AEDT| By SamAlgorae Pharmaceuticals highlights biotech sector activity within All Ordinaries, reflecting research-driven development and healthcare innovation in Australian markets.
ASX Small Caps Highlight Sector Expansion
March 24, 2026 07:26 PM AEDT| By SamASX small-cap activity highlights healthcare innovation and resource exploration, with companies like Recce and American Rare Earths shaping sector developments.
Advertise your brand on Kalkine Media